Actively Recruiting
A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese
Led by Novo Nordisk A/S · Updated on 2026-04-13
100
Participants Needed
1
Research Sites
50 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial is being done to look at the safety and effect of combining cagrilintide and NNC0480-0389 in people living with overweight and obesity compared to taking cagrilintide alone. In one period participants will get two medicines: cagrilintide and NNC0480-0389. In the other period, participants will get cagrilintide together with a placebo version of NNC0480-0389.The placebo looks like the real treatment but does not have any active medicine in it. Cagrilintide and NNC0480-0389 is a new medicine being tested to help people with type 2 diabetes and/or overweight or obesity. The trial medicines is not yet approved for use outside of clinical trials. Participants will receive the trial medicines the way the trial doctor has described. The study will last for about 4.5 months.
CONDITIONS
Official Title
A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female at birth
- Age 18 to 64 years at the time of informed consent
- Body mass index (BMI) between 27.0 and 39.9 kg/m² at screening
- Overweight due to excess adipose tissue as judged by the investigator
- Suitable veins for cannulation or repeated venepuncture as judged by the investigator
- No clinically significant findings in medical history, physical exam, vital signs, ECG, or lab tests at screening
You will not qualify if you...
- Known or suspected allergy to study drugs or related products
- Pregnant, breastfeeding, planning pregnancy, or of childbearing potential not using highly effective contraception
- Currently participating in another interventional clinical study within 90 days before screening
- Any condition that might risk safety or compliance as judged by the investigator
- Use of medication for obesity or weight management, including incretin-based treatments, within 90 days before screening
- Previous or planned obesity surgery during the study period except liposuction, abdominoplasty, adjustable gastric banding removal, intragastric balloon removal, or duodenal-jejunal bypass liner removal if done more than 1 year before screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Parexel Research Unit
Harrow, Middlesex, United Kingdom, HA1 3UJ
Actively Recruiting
Research Team
N
Novo Nordisk
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here